AngioDynamics Statistics
Total Valuation
AngioDynamics has a market cap or net worth of $250.74 million. The enterprise value is $172.29 million.
| Market Cap | 250.74M |
| Enterprise Value | 172.29M |
Important Dates
The last earnings date was Thursday, April 4, 2024, before market open.
| Earnings Date | Apr 4, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AngioDynamics has 40.05 million shares outstanding. The number of shares has increased by 1.84% in one year.
| Shares Outstanding | 40.05M |
| Shares Change (YoY) | +1.84% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | 5.00% |
| Owned by Institutions (%) | 91.13% |
| Float | 38.86M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.77 |
| Forward PS | 0.83 |
| PB Ratio | 1.15 |
| P/FCF Ratio | 2.27 |
| PEG Ratio | 1.87 |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.53 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 1.56 |
Financial Position
The company has a current ratio of 2.29, with zero debt.
| Current Ratio | 2.29 |
| Quick Ratio | 1.49 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 1,366.49 |
Financial Efficiency
Return on equity (ROE) is -54.00% and return on invested capital (ROIC) is -90.96%.
| Return on Equity (ROE) | -54.00% |
| Return on Assets (ROA) | -41.60% |
| Return on Capital (ROIC) | -90.96% |
| Revenue Per Employee | $397,556 |
| Profits Per Employee | -$236,033 |
| Employee Count | 815 |
| Asset Turnover | 0.70 |
| Inventory Turnover | 2.66 |
Taxes
| Income Tax | -7.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.98% in the last 52 weeks. The beta is 0.68, so AngioDynamics's price volatility has been lower than the market average.
| Beta (1Y) | 0.68 |
| 52-Week Price Change | -29.98% |
| 50-Day Moving Average | 5.94 |
| 200-Day Moving Average | 7.00 |
| Relative Strength Index (RSI) | 51.62 |
| Average Volume (30 Days) | 527,987 |
Short Selling Information
The latest short interest is 2.25 million, so 5.62% of the outstanding shares have been sold short.
| Short Interest | 2.25M |
| Short Previous Month | 2.46M |
| Short % of Shares Out | 5.62% |
| Short % of Float | 5.79% |
| Short Ratio (days to cover) | 5.34 |
Income Statement
In the last 12 months, AngioDynamics had revenue of $324.01 million and -$192.37 million in losses. Loss per share was -$4.78.
| Revenue | 324.01M |
| Gross Profit | 162.54M |
| Operating Income | -198.94M |
| Pretax Income | -199.36M |
| Net Income | -192.37M |
| EBITDA | -169.01M |
| EBIT | -199.51M |
| Loss Per Share | -$4.78 |
Balance Sheet
The company has $78.45 million in cash and no debt, giving a net cash position of $78.45 million or $1.96 per share.
| Cash & Cash Equivalents | 78.45M |
| Total Debt | n/a |
| Net Cash | 78.45M |
| Net Cash Per Share | $1.96 |
| Equity / Book Value | 218.70M |
| Book Value Per Share | 5.46 |
| Working Capital | 111.03M |
Cash Flow
In the last 12 months, operating cash flow was -$17.21 million and capital expenditures $127.78 million, giving a free cash flow of $110.57 million.
| Operating Cash Flow | -17.21M |
| Capital Expenditures | 127.78M |
| Free Cash Flow | 110.57M |
| FCF Per Share | $2.75 |
Margins
Gross margin is 50.17%, with operating and profit margins of -61.40% and -59.37%.
| Gross Margin | 50.17% |
| Operating Margin | -61.40% |
| Pretax Margin | -61.53% |
| Profit Margin | -59.37% |
| EBITDA Margin | -52.16% |
| EBIT Margin | -61.58% |
| FCF Margin | 34.13% |
Dividends & Yields
AngioDynamics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.84% |
| Shareholder Yield | -1.84% |
| Earnings Yield | -76.72% |
| FCF Yield | 44.10% |
Analyst Forecast
The average price target for AngioDynamics is $14.25, which is 127.64% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $14.25 |
| Price Target Difference | 127.64% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 7.31% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AngioDynamics has an Altman Z-Score of -0.85 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.85 |
| Piotroski F-Score | 3 |